Cargando…

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up

Tuberous sclerosis complex (TSC) is a genetic multisystem disorder with prominent skin involvement including facial angiofibromas that often appear in early childhood. Here we report the case of a 12-year-old girl with widespread disfiguring facial angiofibromas that were successfully treated with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebrahimi-Fakhari, Daniel, Müller, Cornelia Sigrid Lissi, Meyer, Sascha, Flotats-Bastardas, Marina, Vogt, Thomas, Pföhler, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336437/ https://www.ncbi.nlm.nih.gov/pubmed/28181194 http://dx.doi.org/10.1007/s13555-017-0174-5

Ejemplares similares

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Topical rapamycin (sirolimus) for facial angiofibromas
por: Madke, Bhushan
Publicado: (2013)

Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015)

Nipple angiofibromas with loss of TSC2 are associated with tuberous sclerosis complex
por: Nathan, Neera, et al.
Publicado: (2015)

Facial Angiofibromas and Periungual Fibromas in Tuberous Sclerosis
por: Tsujimoto, Hiraku, et al.
Publicado: (2017)

Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2018)

Correction to: Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2019)

Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex
por: Ghazavi, Mohammadreza, et al.
Publicado: (2023)

Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin Type
por: Viswanath, Vishalakshi, et al.
Publicado: (2016)

Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex
por: Amin, S., et al.
Publicado: (2017)

Isolated Unilateral Facial Angiofibroma or Segmental Tuberous Sclerosis Complex?
por: Supekar, Bhagyashree B., et al.
Publicado: (2021)

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
por: Lin, Yu-Ting, et al.
Publicado: (2022)

Impact of facial angiofibromas in tuberous sclerosis complex and reported efficacy of available treatments
por: Monaghan, Marie, et al.
Publicado: (2022)

Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
por: Hatano, Takashi, et al.
Publicado: (2020)

Managing Different Spectrums of Tuberous Sclerosis Facial Angiofibroma: A Report of Two Cases
por: Mustaqim, Khairul, et al.
Publicado: (2023)

Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial
por: Wheless, Margaret C., et al.
Publicado: (2019)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Dermoscopy of facial angiofibromas in Fitzpatrick II‐III phototype subjects affected by tuberous sclerosis complex
por: Lacarrubba, Francesco, et al.
Publicado: (2023)

Dermoscopy of Facial Angiofibromas in Four Patients of Skin of Color with Tuberous Sclerosis Complex: A Case-Series
por: Jindal, Rashmi, et al.
Publicado: (2021)

The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)
por: Feliciano, David M.
Publicado: (2020)

Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex
por: Okanishi, Tohru, et al.
Publicado: (2020)

Atypical cutaneous presentation of tuberous sclerosis complex: Giant angiofibroma on the scalp
por: Freitas, Leonardo Furtado, et al.
Publicado: (2021)

Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complex
por: Li, Yi, et al.
Publicado: (2018)

Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex
por: Rosengren, Thomas, et al.
Publicado: (2020)

Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database
por: Boggarapu, Sreedevi, et al.
Publicado: (2022)

Socio-epidemiologic aspects and cutaneous side effects of permanent tattoos in Germany – Tattoos are not restricted to a specific social phenotype
por: Müller, Cornelia Sigrid Lissi, et al.
Publicado: (2016)

Bronchial angiofibroma in tuberous sclerosis complex: A case report and literature review
por: Teng, Peikun, et al.
Publicado: (2021)

Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers
por: Mühlebner, Angelika, et al.
Publicado: (2020)

tsc2 mutant zebrafish model of tuberous sclerosis complex
Publicado: (2011)

TSC1 Mutations in Keratoconus Patients With or Without Tuberous Sclerosis
por: Bykhovskaya, Yelena, et al.
Publicado: (2017)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece
por: Avgeris, Socratis, et al.
Publicado: (2017)

Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis
por: Rosset, Clévia, et al.
Publicado: (2017)

TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review
por: Rosset, Clévia, et al.
Publicado: (2017)

Corrigendum: Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2019)

Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2018)

Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?
por: Chan, Jung-Yi Lisa, et al.
Publicado: (2014)

Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care
por: Annear, Nicholas M. P., et al.
Publicado: (2019)

The importance of imaging in tuberous sclerosis complex (tsc) in children: Two cases
por: Dedushi, Kreshnike, et al.
Publicado: (2021)

Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM
por: Müller, Annelieke R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o1kg863bfpqa48qvnt4becbj2u